🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsBuyer Beware⚠ Compounding pharmacies with FDA 483 observations — need advice

⚠ Compounding pharmacies with FDA 483 observations — need advice

Dr.ObesityLA Wed, Jul 30, 2025 at 8:14 AM 14 replies 1,519 viewsPage 1 of 3
This thread is more than 10 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Jul 30, 2025 at 8:14 AM#1

Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within weeks of each other.

The question I want answered is what actually distinguishes 503A from 503B, in terms of what each may make and from what starting material.

I have searched first, so if this is covered somewhere point me at it and I will read it.

19 14zoe_NC, Dr.ObesityLA, NurseKim_ATL and 16 others
Reply Quote Save Share Report
DanielChem_CHI
Senior Member
1,234
5,678
Mar 2024
Chicago, IL
Jul 30, 2025 at 9:37 AM#2

Short answer first, then the reasoning. The shortage clause is the answer to the second question and it is a subtraction rather than an addition. Both exemptions forbid compounding something that is essentially a copy of a commercially available approved product. A product FDA has listed as in shortage is not treated as commercially available, so listing removed the objection that otherwise blocked compounding. It never created a permission; it withdrew a prohibition, which is why it evaporated the moment the supply fact changed.

Last edited: Jul 30, 2025 at 11:37 AM
18 13Dr.DermMIA, fiona_VT, denise_HTX and 15 others
Reply Quote Save Share Report
tom_AK
New Member
28
112
Jan 2026
Anchorage, AK
Jul 30, 2025 at 11:00 AM#3
DanielChem_CHI said:
The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

Agreed, and the enforcement dates were staggered by category — 503A first, 503B a few weeks later — because outsourcing facilities have manufactured inventory and clinic contracts to unwind while a 503A makes to order.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

17 12tyler_CSCS, VanRx_Mike, steve_okc and 14 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
sophie_paris
Member
212
890
Nov 2024
Paris, FR
Jul 30, 2025 at 12:23 PM#4
Dr.ObesityLA said:
Two pharmacies quoted me last year, one describing itself as 503A and one as 503B, and I assumed 503B just meant bigger until both stopped within…

Can confirm the pattern Dr.ObesityLA describes. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

Last edited: Jul 30, 2025 at 5:23 PM
16 11AussieAnna, BethLabQueen, ChrisMacros and 13 others
Reply Quote Save Share Report
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jul 30, 2025 at 8:29 PM#5

Adding the clinical framing, because it changes how the question reads.

Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness. A pharmacy that can't answer questions promptly is a red flag.

My current pharmacy: average response time same day. They answered my questions about sterility testing thoroughly and professionally.

Communication quality is a proxy for operational quality. A pharmacy that communicates well is likely manufacturing well too.

15 10KristenIndy, MarkLI_maint, Dr.PeteFamMed and 12 others
Reply Quote Save Share Report

Similar Threads

⚠ Peptide Sciences SHUT DOWN March 6, 2026 — what happened and what to do now8 replies
⚠ Amino Asylum raided by FDA June 2025 — warehouse seized6 replies
⚠ Swiss Chems FDA warning letter December 2024 — selling unapproved drugs6 replies
⚠ 50+ FDA warning letters sent to peptide vendors in 2025 — full list4 replies
⚠ PeptideMeter exposed: some vendors scoring E grade on basic peptides4 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register